Press Releases

June 9, 2022
Gossamer Bio Announces Publication of Key Preclinical Data in the European Respiratory Journal Highlighting Seralutinib’s Potential for the Treatment of PAH
SAN DIEGO --(BUSINESS WIRE)--Jun. 9, 2022-- Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced the publication of
Additional Formats